Literature DB >> 9695795

Optic nerve blood-flow abnormalities in glaucoma.

J Flammer1, S Orgül.   

Abstract

Glaucoma can be defined as an optic nerve disease with typical morphological and functional changes. There are many risk factors associated with this neuropathy. The best known factor is an increased intraocular pressure. There are, however, many other risk factors. Among them, vascular factors play a major role. Although such vascular factors have been postulated more than hundred years ago, it is only recently that the physiology and pathophysiology of the optic nerve head circulation is, to some extent, understood. New instruments have been developed to measure ocular blood flow including blood flow in the optic nerve head. Although most of the studies indicate that circulation is changed in glaucoma patients, there is little association between glaucoma and arteriosclerosis. The main cause for the circulation disturbance in glaucoma seems rather to be a vascular dysregulation leading to local vasospasm and to systemic hypotension.

Entities:  

Mesh:

Year:  1998        PMID: 9695795     DOI: 10.1016/s1350-9462(97)00006-2

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  86 in total

Review 1.  Ganglion cell death in glaucoma: what do we really know?

Authors:  N N Osborne; J P Wood; G Chidlow; J H Bae; J Melena; M S Nash
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

Review 2.  A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma.

Authors:  N N Osborne; J Melena; G Chidlow; J P Wood
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

3.  Factors affecting the use of multifocal electroretinography to monitor function in a primate model of glaucoma.

Authors:  Brad Fortune; Grant Cull; Lin Wang; E Michael Van Buskirk; George A Cioffi
Journal:  Doc Ophthalmol       Date:  2002-09       Impact factor: 2.379

Review 4.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

5.  Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients.

Authors:  A Gass; J Flammer; L Linder; S C Romerio; P Gasser; W E Haefeli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-10       Impact factor: 3.117

6.  Retrobulbar haemodynamics and morphometric optic disc analysis in primary open-angle glaucoma.

Authors:  N Plange; M Kaup; A Weber; K O Arend; A Remky
Journal:  Br J Ophthalmol       Date:  2006-08-16       Impact factor: 4.638

7.  Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma.

Authors:  A Luksch; G Rainer; D Koyuncu; P Ehrlich; T Maca; M E Gschwandtner; C Vass; L Schmetterer
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

8.  Systemic Determinants of Peripapillary Vessel Density in Healthy African Americans: The African American Eye Disease Study.

Authors:  Ryuna Chang; Andrew J Nelson; Vivian LeTran; Brian Vu; Bruce Burkemper; Zhongdi Chu; Ali Fard; Amir H Kashani; Benjamin Y Xu; Ruikang K Wang; Rohit Varma; Grace M Richter
Journal:  Am J Ophthalmol       Date:  2019-06-21       Impact factor: 5.258

9.  Integrins in the optic nerve head: potential roles in glaucomatous optic neuropathy (an American Ophthalmological Society thesis).

Authors:  John C Morrison
Journal:  Trans Am Ophthalmol Soc       Date:  2006

10.  Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram.

Authors:  Benedetto Falsini; Dario Marangoni; Tommaso Salgarello; Giovanna Stifano; Lucrezia Montrone; Salvatore Di Landro; Laura Guccione; Emilio Balestrazzi; Alberto Colotto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-03-17       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.